The Commons
Slamming Cancer: A Conversation with Steve Potts, CEO of SLAM BioTherapeutics
Commons host, Thomas Osha, catches up with serial entrepreneur, Steve Potts, to discuss his latest venture, SLAM BioTherapeutics. Slam Bio is developing a platform of first-in-class monoclonal antibody therapies and antibody-drug conjugates (ADCs) targeting cancer, beginning with blood cancers.
The conversation took place at the BIO International Conference 2024 in San Diego June 4-6, 2024.
https://slambio.com/
Commons host, Thomas Osha, catches up with serial entrepreneur, Steve Potts, to discuss his latest venture, SLAM BioTherapeutics. Slam Bio is developing a platform of first-in-class monoclonal antibody therapies and antibody-drug conjugates (ADCs) targeting cancer, beginning with blood cancers.
The conversation took place at the BIO International Conference 2024 in San Diego June 4-6, 2024.
https://slambio.com/